In a 46-year-old male with a positive anti‑HCV antibody, HCV RNA of 2,283,553 IU/mL, normal liver function tests, normal abdominal ultrasound, and normal FibroScan, what is the appropriate management?

Initiate Direct-Acting Antiviral (DAA) Treatment Immediately

This 46-year-old male with confirmed chronic HCV infection (positive anti-HCV antibody and detectable HCV RNA at 2,283,553 IU/mL) should proceed directly to antiviral treatment with pangenotypic DAAs, regardless of the absence of significant fibrosis. 1

Rationale for Treatment

The goal of HCV treatment is to eradicate the virus and prevent progression to cirrhosis, hepatocellular carcinoma, extrahepatic manifestations, and death 1. While your patient currently has:

• Normal liver function tests
• Normal ultrasound
• Normal FibroScan (indicating no significant fibrosis or cirrhosis)

Modern guidelines recommend treating all patients with confirmed chronic HCV infection, not just those with advanced fibrosis 1, 2. The 2016 KASL guidelines explicitly state that "all treatment-naïve patients with compensated disease because of HCV should be considered for therapy" 1.

Pre-Treatment Steps Required

Before initiating treatment, you must complete 1:

1. HCV genotyping/subgenotyping (1a/1b) - Essential for treatment selection
2. HCV RNA quantitative assay - Already done (2,283,553 IU/mL)
3. Complete blood count - Check platelet count
4. Calculate FIB-4 score using: age × AST / (platelet count × √ALT)
   • FIB-4 <1.45 confirms absence of advanced fibrosis (90% negative predictive value) 1
5. Medication reconciliation - Screen for drug-drug interactions 3

Treatment Recommendations

For Treatment-Naïve Patients Without Cirrhosis:

First-line options 4, 5:

• Glecaprevir/pibrentasvir (Maviret): 8 weeks duration
• Sofosbuvir/velpatasvir (Epclusa): 12 weeks duration

Both regimens are pangenotypic (effective against all HCV genotypes) and achieve >95% sustained virologic response (SVR) rates in non-cirrhotic patients 4, 5.

Treatment Selection Based on Genotype:

Once genotyping results are available:

• Genotype 1 or 4: Either regimen works excellently
• Genotype 2: Both regimens effective
• Genotype 3: May require genotype-specific considerations if cirrhosis develops later 1

On-Treatment Monitoring

Minimal monitoring is required for non-cirrhotic patients 3:

• No routine laboratory monitoring needed during treatment
• Educate patient about proper medication adherence
• Counsel on prevention of reinfection
• Consider telehealth/phone check-in for support

Important caveats:

• If patient takes diabetes medications: Monitor for hypoglycemia (HCV cure can improve glucose control) 3
• If patient takes warfarin: Monitor INR for subtherapeutic anticoagulation 3

Post-Treatment Assessment

At 12 weeks after completing therapy 1, 3, 5:

• Check quantitative HCV RNA (should be undetectable)
• Check liver function tests (transaminases should normalize)
• Undetectable HCV RNA at 12 weeks = sustained virologic response (SVR) = virologic cure
• 99% of patients achieving SVR remain HCV-free permanently 1

Follow-Up After Achieving SVR

For patients without cirrhosis who achieve SVR 3, 5:

• No liver-related follow-up is required
• No need for ongoing HCC surveillance
• No need for endoscopic surveillance
• Assess for other causes of liver disease if transaminases remain elevated

If patient has ongoing risk factors (injection drug use, high-risk sexual behavior) 3:

• Counsel about risk reduction
• Test HCV RNA annually to detect reinfection
• Reinfection requires retreatment but does not indicate treatment failure

Common Pitfalls to Avoid

1. Do not delay treatment waiting for fibrosis progression - treat now to prevent complications 1, 2
2. Do not use interferon-based regimens - DAAs are superior in efficacy, safety, and duration 1, 5
3. Do not skip genotyping - required before treatment initiation 1
4. Do not order unnecessary monitoring - overtesting increases costs without benefit in non-cirrhotic patients 3
5. Do not assume normal LFTs mean no treatment needed - HCV RNA levels do not correlate with disease severity 6

Counseling Points

• Alcohol avoidance: Strongly recommend abstinence to prevent disease progression 2
• Hepatitis A vaccination: Recommended because fulminant hepatitis risk increases with HCV coinfection 7
• Transmission prevention: Counsel on avoiding blood/body fluid exposure, not sharing personal care items 2, 7

The bottom line: Your patient has curable chronic HCV infection. Complete pre-treatment genotyping, initiate pangenotypic DAA therapy, and expect >95% cure rate with minimal monitoring requirements.